Back

Prevalence of Neutralizing Antibodies against Adenoviruses types -C5, -D26 and -B35 used in vaccination platforms, in Healthy and HIV-Infected Adults and Children from Burkina Faso and Chad

Ouoba, A. R.; Paris, O.; Adawaye, C.; Dzomo, G. T.; Fouda, A. A.; Kania, D.; Diarra, A.; Kallo, Z. A.; Traore, I. T.; Sirima, S. B.; Tuaillon, E.; Van de Perre, P.; Kremer, E. J.; Mennechet, F. J. D.

2022-06-07 epidemiology
10.1101/2022.06.07.22276076 medRxiv
Show abstract

Vaccines derived from human adenoviruses (HAdV) are currently being used and trialed against numerous infectious agents. However, pre-existing humoral immunity can impair vaccines efficacy and safety. Strategies to circumvent this immunity often involve the use of vectors with lower seroprevalence. We evaluated HAdV-C5, HAdV-D26 and HAdV-B35 seroprevalence from healthy and HIV-infected populations from Burkina Faso and Chad. Seroprevalence for HAdV-C5 was high and comparable between countries (54%-66%), and the highest in the HIV-infected groups from sub-Saharan regions ([~]90%). However, compared to France (4%), seroprevalence for HAdV-D26 was significantly higher in sub- Saharan groups ([~]47%). By contrast, HAdV-B35 seroprevalence was low for all groups tested. We also found that HAdV-D26 complexed with immunoglobulins induced strong activation of dendritic cells in vitro. Our study fills gaps in the epidemiological data needed to optimize HAdV-derived vaccines in sub-Saharan regions, and highlights the necessity to better adjust vaccination strategies in Africa. Article summary lineHAdVs Seroprevalence in Burkina Faso and Chad

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.